Literature DB >> 2480168

Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.

J E Souness1, R Brazdil, B K Diocee, R Jordan.   

Abstract

1. The mechanism by which M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine (MIMAX), which have been described as selective cyclic GMP phosphodiesterase (PDE) inhibitors, relax rat aorta was investigated. 2. Three cyclic nucleotide PDEs were identified in the soluble fraction of rat aorta; a Ca2+-insensitive form exhibiting substrate selectivity for cyclic GMP (cGMP PDE), a Ca2+/calmodulin-stimulated form which also preferentially hydrolyzed cyclic GMP (Ca2+ PDE), and a form demonstrating substrate selectivity for cyclic AMP (cAMP PDE). 3. M&B 22,948 and MIMAX inhibited cGMP PDE (Ki = 0.16 microM and 0.43 microM, respectively) and Ca2+ PDE (Ki = 9.9 microM and 0.55 microM, respectively), but exhibited weak activity against cAMP PDE (Ki = 249 microM and 42 microM, respectively). MY-5445 selectivity inhibited cGMP PDE (Ki = 1.3 microM) and vinpocetine selectively inhibited Ca2+ PDE (Ki = 14 microM). 4. M&B 22,948 and MIMAX induced dose-dependent increases in the accumulation of cyclic GMP, but not cyclic AMP, in rat aorta pieces. These effects were greatly reduced by endothelial denudation and by methylene blue (5 microM) which blocks the actions of endothelium-derived relaxant factor. MY-5445 and vinpocetine had no effect on rat aorta cyclic GMP or cyclic AMP accumulation. 5. All four compounds caused dose-related relaxation of 5-hydroxytryptamine (10 microM) contracted, endothelium-intact rat aorta, the effects of M&B 22,948 and MIMAX being greatly reduced by methylene blue (5 microM). Methylene blue also caused 10 fold and 100 fold rightward shifts in the dose-response curves of MY-5445 and vinpocetine, respectively. 6. The results are consistent with the smooth muscle relaxant actions of M&B 22,948 and MIMAX, but not vinpocetine and MY-5445, being mediated through a mechanism involving inhibition of cyclic GMP hydrolysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2480168      PMCID: PMC1854783          DOI: 10.1111/j.1476-5381.1989.tb14599.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

Review 1.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.

Authors:  W J Thompson; W L Terasaki; P M Epstein; S J Strada
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.

Authors:  R E Weishaar; M H Cain; J A Bristol
Journal:  J Med Chem       Date:  1985-05       Impact factor: 7.446

4.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.

Authors:  C Lugnier; P Schoeffter; A Le Bec; E Strouthou; J C Stoclet
Journal:  Biochem Pharmacol       Date:  1986-05-15       Impact factor: 5.858

5.  Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor.

Authors:  W Martin; R F Furchgott; G M Villani; D Jothianandan
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

6.  Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation.

Authors:  M Hagiwara; T Endo; T Kanayama; H Hidaka
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

7.  Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors.

Authors:  K L Lorenz; J N Wells
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

8.  Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta.

Authors:  W Martin; G M Villani; D Jothianandan; R F Furchgott
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

9.  Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscle.

Authors:  A Bowman; A H Drummond
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

10.  Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle.

Authors:  M Hagiwara; T Endo; H Hidaka
Journal:  Biochem Pharmacol       Date:  1984-02-01       Impact factor: 5.858

View more
  10 in total

1.  The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung.

Authors:  F Burns; I W Rodger; N J Pyne
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

2.  Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.

Authors:  Fernanda R Giachini; Victor V Lima; Fernando S Carneiro; Rita C Tostes; R Clinton Webb
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

Review 3.  Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

Authors:  T J Torphy; B J Undem
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

Review 4.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

6.  Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog.

Authors:  H Yamada; F Yoneyama; K Satoh; N Taira
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

7.  Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.

Authors:  A H Cohen; K Hanson; K Morris; B Fouty; I F McMurty; W Clarke; D M Rodman
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

8.  Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.

Authors:  Clint L Miller; Masayoshi Oikawa; Yujun Cai; Andrew P Wojtovich; David J Nagel; Xiangbin Xu; Haodong Xu; Vince Florio; Sergei D Rybalkin; Joseph A Beavo; Yiu-Fai Chen; Jian-Dong Li; Burns C Blaxall; Jun-ichi Abe; Chen Yan
Journal:  Circ Res       Date:  2009-09-24       Impact factor: 17.367

9.  Cyclic nucleotide phosphodiesterase 1 and vascular aging.

Authors:  Chen Yan
Journal:  Clin Sci (Lond)       Date:  2015-09-15       Impact factor: 6.124

10.  Vinpocetine Protects Against Cerebral Ischemia-Reperfusion Injury by Targeting Astrocytic Connexin43 via the PI3K/AKT Signaling Pathway.

Authors:  Mingming Zhao; Shuai Hou; Liangshu Feng; Pingping Shen; Di Nan; Yunhai Zhang; Famin Wang; Di Ma; Jiachun Feng
Journal:  Front Neurosci       Date:  2020-04-02       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.